Given that VEGF has consistently shown promise as a biomarker for TBM [15, 22–24] and that we identified other candidate biomarkers with strong potential in the present study, we wondered whether the previous 3-marker VEGF-based biosignature could be further optimized using other analytes. The gene discussed is VEGFA; the disease is meningeal tuberculosis.